Irinotecan plus fuorouracil/ leucovorin as the first-line in treatment of 37 patients with advanced colorectal cancer
- VernacularTitle:伊立替康联合氟尿嘧啶/亚叶酸钙方案一线治疗37例晚期大肠癌
- Author:
Honggang ZHANG
;
Fang WU
;
Shanshan CHEN
- Publication Type:Journal Article
- Keywords:
advanced colorectal cancer;
drug therapy;
irinotecan;
fuorouracil
- From:China Oncology
2006;0(12):-
- CountryChina
- Language:Chinese
-
Abstract:
Background and purpose:Irinotecan plus fuorouracil/Leucovorin has become the standard regimen as the first-line in treating advanced colorectal cancer.We investigated the clinical response and side-effects of the first-line treatment with Irinotecan plus fuorouracil/ leucovorin(FOLFIRI) for advanced colorectal cancer.Methods:From may 2001 to march 2005,37 patients with advanced colorectal cancer were treat with irinotecan 180mg/m~(2) i.v.on day 2,and fuorouracil 400 mg/m~(2),bolus on day 1,2 and 1200 mg/m~(2),civ.44hour;leucovorin 200 mg/m~(2) i.v.on day 1,2,two weeks per cycle.Results:The response rate was 41.7%.Incidence of III/IV Grade myelosuppression was 35.1%/8.1%,and 4 patients suffered from febrile neutropenia.Incidence of III Grade delayed diarrhea was 8.1%.Conclusions:The first-line chemotherapy with a combination of irinotecan and fuorouracil/ leucovorin is effictive and well tolerated by patients with advanced colorectal cancer.
